Lipid and Lipoprotein Disorders

Current Clinical Solutions - Lipid and Lipoprotein Disorders

Lipids Guidelines Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/76511

Contents of this Issue

Navigation

Page 7 of 27

Diagnosis and Assessment of Disease Figure 6. LDL Particle Composition Factors Affecting Lipoprotein Core Lipid Composition (Figs 4 and 5) ÎTG-rich lipoproteins, using cholesteryl ester transfer protein (CETP), exchange TG for CE molecules leading to TG-rich and CE-poor LDL and HDL, and TG-poor and CE-rich VLDLs. ÎThis, in turn, leads to reductions in LDL-C and HDL-C and elevations in VLDL-C and non-HDL-C. ÎThe TG-rich and CE-poor LDL and HDL, upon exposure to hepatic lipase, lose TG and surface phospholipids and become smaller LDL and HDL particles. • Small LDL particles have delayed clearance by LDL receptors. ▶ This increases small LDL-P and total LDL-P (and apoB). ▶ The small HDL-P are subject to catabolism and metabolism of apoA-I by the kidneys, leading to reductions in HDL-P, apoA-I, and HDL-C. • With rare exceptions (Type I, III, V lipoprotein disorders), over 90% of apoB particles are LDL. • Characteristically, such patients have high apoB (LDL-P and VLDL remnants) and low apoA-I (total HDL-P) (elevated apoB/apoA-I or LDL-P/HDL-P ratios). • Until proven otherwise, assume that patients with low HDL-C have too many LDL particles (elevated apoB and LDL-P) and reduced large HDL-P. • Increased large VLDL-P and VLDL size, increased small LDL-P, decreased LDL size, decreased HDL size and large HDL-P are lipoprotein markers of insulin resistance. ÎHigh TG and reduced HDL-C are characteristically accompanied by elevated apoB (> 90% of these being LDL particles), elevated LDL-P, and reduced apoA-I (HDL-P). 6

Articles in this issue

Archives of this issue

view archives of Lipid and Lipoprotein Disorders - Current Clinical Solutions - Lipid and Lipoprotein Disorders